AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 8608485
Drug: Continuous infusion
RxNorm normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous infusion 5-fluorouracil (5-FU) at doses ranging from 200-1100 mg/m2/day for 4 days
Trial: 27834686
Drug: Enalapril (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enalapril (10 mg) alone
Trial: 1768563
Drug: Enalapril (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enalapril (10 mg) + Indomethacin (75 mg) + Ketotifen (1 mg)
Trial: 1768563
Drug: Enalapril (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enalapril (10 mg) + Indomethacin (75 mg)
Trial: 6816343
Drug: Tablets and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablets and capsules taken with 100 ml of water
Trial: 6816343
Drug: Tablets and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablets and capsules taken with 25 ml of water
Trial: 6816343
Drug: Tablets and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablets and capsules taken while recumbent
Trial: 6816343
Drug: Tablets and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablets and capsules taken while standing
Trial: 6816343
Drug: Small tablets
RxNorm normalized name: smallpox vaccine live, New York City Board of Health vaccinia strain Injectable Solution [ACAM2000]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Small tablets
Trial: 6816343
Drug: Liquid forms
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liquid forms of medication (suspensions)
Trial: 26797227
Drug: Emotional Freedom
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Emotional Freedom Techniques (EFT) group treatment program
Trial: 15660024
Drug: Atorvastatin (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin (all doses)
Trial: 24888199
Drug: Atorvastatin (higher
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin (higher doses)
Trial: 21186930
Drug: 1.8 ml/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.8 ml/kg energy drink
Trial: 21186930
Drug: 3.6 ml/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3.6 ml/kg energy drink
Trial: 21186930
Drug: 5.4 ml/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5.4 ml/kg energy drink
Trial: 17592240
Drug: Sham injection
RxNorm normalized name: BLACK BEAN ANTI HAIR LOSS SHAM POO SET KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham injection (natural course)
Trial: 12379552
Drug: Fluticasone propionate
RxNorm normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Fluticasone propionate and salmeterol combination (FSC)
Trial: 10080557
Drug: Fluphenazine decanoate
RxNorm normalized name: Fluphenazine Decanoate
DrugBank: Fluphenazine (DB00623)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fluphenazine decanoate injections every 2 weeks
Trial: 10080557
Drug: Fluphenazine decanoate
RxNorm normalized name: Fluphenazine Decanoate
DrugBank: Fluphenazine (DB00623)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fluphenazine decanoate injections every 6 weeks
Trial: 27197855
Drug: Glucose alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glucose alone (25 g)
Trial: 27197855
Drug: Whey protein
RxNorm normalized name: Whey protein
DrugBank: Whey (DB18685)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Whey protein (10 g) + glucose (15 g)
Trial: 16652071
Drug: Gabapentin (peak
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gabapentin (peak dose of 2,400 mg/d over 20 weeks)
Trial: 16652071
Drug: Gabapentin (1,800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gabapentin (1,800 and 2,400 mg/day)
Trial: 9336134
Drug: Accelerated Hyperfractionated
RxNorm normalized name: Serum prothrombin conversion accelerator
DrugBank: Coagulation factor VII human (DB13150)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Accelerated Hyperfractionated (AH) radiotherapy (1.6 Gy b.i.d. to a total dose of 54.4 Gy)
Trial: 9336134
Drug: Accelerated Fractionation
RxNorm normalized name: LIVER FRACTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Accelerated Fractionation (AF) of 30 Gy in 10 daily fractions
Trial: 3887172
Drug: Amitriptyline (mean
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amitriptyline (mean dose: 57.8 mg per day, max 75 mg per day)
Trial: 30024193
Drug: Therapists' affiliative
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Therapists' affiliative tendencies and time elapsed in therapy
Trial: 25395314
Drug: Chemotherapy (6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy (6 × 3-weekly cycles FE₁₀₀C)
Trial: 25395314
Drug: Endocrine therapy
RxNorm normalized name: ENDOCRINE THERAPY
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endocrine therapy (letrozole 2.5 mg, daily for 18-23 weeks)
Trial: 20146793
Drug: Supervised Nordic
RxNorm normalized name: modified Vaccinia Ankara-Bavarian Nordic Injection [Jynneos]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supervised Nordic walking twice a week for eight weeks
Trial: 17459096
Drug: Micronized fenofibrate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Micronized fenofibrate 200 mg/day (F group)
Trial: 17459096
Drug: Orlistat 120
RxNorm normalized name: orlistat 120 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Orlistat 120 mg three times daily (O group)
Trial: 17459096
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of orlistat and fenofibrate (OF group)
Trial: 16189259
Drug: Telepaque (iopanoic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Telepaque (iopanoic acid), 500 mg/d orally for 7 days
Trial: 16189259
Drug: 131I therapy
RxNorm normalized name: tetracycline
DrugBank: Tetracycline (DB00759)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 131I therapy after Telepaque
Trial: 16189259
Drug: Carbimazole, 30-40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carbimazole, 30-40 mg daily until euthyroid followed by 131I
Trial: 8885674
Drug: SPf66 malaria
RxNorm normalized name: PLASMODIUM MALARIAE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SPf66 malaria vaccine (1st dose)
Trial: 8885674
Drug: SPf66 malaria
RxNorm normalized name: PLASMODIUM MALARIAE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SPf66 malaria vaccine (2nd dose)
Trial: 8885674
Drug: SPf66 malaria
RxNorm normalized name: PLASMODIUM MALARIAE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SPf66 malaria vaccine (3rd dose)
Trial: 8885674
Drug: Placebo (1st
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (1st dose)
Trial: 8885674
Drug: Placebo (2nd
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (2nd dose)
Trial: 8885674
Drug: Placebo (3rd
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (3rd dose)
Trial: 8885674
Drug: SPf66 malaria
RxNorm normalized name: PLASMODIUM MALARIAE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SPf66 malaria vaccine (local reactions)
Trial: 8885674
Drug: SPf66 malaria
RxNorm normalized name: PLASMODIUM MALARIAE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SPf66 malaria vaccine (systemic side effects)
Trial: 2065925
Drug: Ursodeoxycholic acid
RxNorm normalized name: Ursodeoxycholic acid
DrugBank: Ursodeoxycholic acid (DB01586)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ursodeoxycholic acid (10 mg.kg‐1.day‐1 for 1 month)
Trial: 2065925
Drug: Chenodeoxycholic acid
RxNorm normalized name: Chenodeoxycholic acid
DrugBank: Chenodeoxycholic acid (DB06777)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chenodeoxycholic acid (15 mg.kg‐1.day‐1 for 1 month)
Trial: 6587751
Drug: Verapamil (Isoptin)
RxNorm normalized name: verapamil Extended Release Oral Tablet [Isoptin]
DrugBank: Verapamil (DB00661)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Verapamil (Isoptin) 120 mg X 3 for four weeks
Trial: 22927454
Drug: intermittent dosing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: intermittent dosing schedule of aerosolized ribavirin
Trial: 22927454
Drug: continuous dosing
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: continuous dosing schedule of aerosolized ribavirin
Trial: 16286540
Drug: Interferon beta-1a
RxNorm normalized name: interferon beta-1a
DrugBank: Interferon beta-1a (DB00060)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Interferon beta-1a (30-microg, once weekly, intramuscular)
Trial: 10371118
Drug: Chemotherapy (PVM:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy (PVM: 80 mg/m2 Cisplatin on day 1, 2-3 mg/m2 Vindesine on day 1 and/or day 8, 8 mg/m2 Mitomycin C on day 1, followed by 400 mg/day UFT orally for 1 year)
Trial: 10371118
Drug: Chemotherapy (PVM)
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy (PVM)
Trial: 29783900
Drug: Fluoxetine (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoxetine (20 mg PO daily)
Trial: 29783900
Drug: Citalopram (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Citalopram (20 mg PO daily)
Trial: 24503429
Drug: Warfarin prescribed
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Warfarin prescribed according to predicted warfarin dose based on VKORC1 and CYP2C9 genotypes
Trial: 24503429
Drug: Warfarin prescribed
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Warfarin prescribed according to empirical clinician estimates
Trial: 24503429
Drug: Average predicted
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Average predicted dose for stable dose patients
Trial: 24503429
Drug: Average effective
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Average effective dose for stable dose patients
Trial: 24503429
Drug: Difference between
RxNorm normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Difference between average predicted dose and actual dose
Trial: 16191240
Drug: Donepezil (acetylcholinesterase
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Donepezil (acetylcholinesterase inhibitor), dosage and duration not specified
Trial: 8853805
Drug: Immunoadsorption therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immunoadsorption therapy utilizing Prosorba column
Trial: 8853805
Drug: Immunoadsorption therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immunoadsorption therapy
Trial: 1346539
Drug: Pilopine Gel
RxNorm normalized name: pilocarpine hydrochloride Ophthalmic Gel [Pilopine]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pilopine Gel (pilocarpine hydrochloride)
Trial: 28872380
Drug: Low-intensity training
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-intensity training (HA-L)
Trial: 18651608
Drug: 750 mg
RxNorm normalized name: bran 750 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 750 mg nabumetone tablet formulation
Trial: 17121035
Drug: Antibiotic plus
RxNorm normalized name: Triple Antibiotic Plus
DrugBank: Polymyxin B (DB00781)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Antibiotic plus vitamin E (Control)
Trial: 31519364
Drug: Intrapleural fibrinolytic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intrapleural fibrinolytic therapy (IFT)
Trial: 30806130
Drug: Mixed pure
RxNorm normalized name: Humalog Mix
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mixed pure tones sound therapy
Trial: 30806130
Drug: Broad band
RxNorm normalized name: Band-Aid Hurt-Free
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Broad band noise (BBN) sound therapy
Trial: 28831695
Drug: Simplest model
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simplest model for insulin pharmacokinetics
Trial: 28831695
Drug: Best model
RxNorm normalized name: calcium polycarbophil
DrugBank: Calcium polycarbophil (DB14684)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Best model with two linear subcutaneous compartments
Trial: 26425555
Drug: CC haplotype
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CC haplotype (rs969885-rs987195)
Trial: 19681940
Drug: Immediate loading
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate loading of two bar‐splinted SLActive implants with an implant‐retained mandibular overdenture
Trial: 11443604
Drug: 18 grays
RxNorm normalized name: Baccharis sarothroides a.gray
DrugBank: Baccharis sarothroides whole (DB15502)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 18 grays (Gy) of cranial radiation therapy
Trial: 8576295
Drug: mebeverine plain
RxNorm normalized name: mebeverine
DrugBank: Mebeverine (DB12554)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: mebeverine plain 135 mg, two capsules t.i.d.
Trial: 8576295
Drug: mebeverine sustained
RxNorm normalized name: mebeverine
DrugBank: Mebeverine (DB12554)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: mebeverine sustained release 200 mg (SR), two capsules b.i.d.
Trial: 8576295
Drug: Both formulations
RxNorm normalized name: Bothrops atrox venom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both formulations (mebeverine plain and mebeverine SR)
Trial: 2142109
Drug: Danazol (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Danazol (600 mg a day)
Trial: 2142109
Drug: High-dose medroxyprogesterone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose medroxyprogesterone acetate (MPA; 100 mg a day)
Trial: 357069
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg fenmetozole
Trial: 357069
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of 200 mg fenmetozole and 50 ml/70 kg ethanol
Trial: 19752581
Drug: 600 mg/day
RxNorm normalized name: Rebetron, single dose 600 mg/day oral and injectable kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 600 mg/day of ARA-enriched triglyceride (SUNTGA40S; containing 240 mg ARA)
Trial: 19752581
Drug: Olive oil
RxNorm normalized name: Olive Oil
DrugBank: Olive oil (DB09567)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olive oil capsules (inactive placebo)
Trial: 8891660
Drug: Control (pre-L-dopa
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (pre-L-dopa administration)
Trial: 4027125
Drug: Activated charcoal
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Activated charcoal (2.5 g) administered 1 h after mefenamic acid
Trial: 4027125
Drug: Activated charcoal
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Activated charcoal (2.5 g) and hyoscine butylbromide (20 mg) administered after mefenamic acid
Trial: 4027125
Drug: Hyoscine butylbromide
RxNorm normalized name: Hyoscine butylbromide
DrugBank: Butylscopolamine (DB09300)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hyoscine butylbromide (20 mg) administered immediately after mefenamic acid
Trial: 25159085
Drug: Bright light
RxNorm normalized name: kaolin light
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bright light therapy (5,000 lx)
Trial: 22729470
Drug: Structum (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Structum (500 mg twice daily)
Trial: 18451114
Drug: Haloperidol 2
RxNorm normalized name: haloperidol 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Haloperidol 2 mg iv during induction of anesthesia
Trial: 18451114
Drug: Haloperidol 2
RxNorm normalized name: haloperidol 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Haloperidol 2 mg iv approximately 30 min before the end of surgery
Trial: 18451114
Drug: Haloperidol 2
RxNorm normalized name: haloperidol 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Haloperidol 2 mg iv (both groups)
Trial: 16416368
Drug: Conventional diet
RxNorm normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional diet supplying 35 nonprotein kcal and 1.1 g of protein/kg per day (group A, n = 11)
Trial: 14569405
Drug: LCP supplemented
RxNorm normalized name: LCP-AtorFen
DrugBank: LCP-AtorFen (DB05769)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LCP supplemented formula (0.5 g/100 g fat linoleic acid metabolites, 0.8 g/100 g fat alpha‐linolenic acid metabolites)
Trial: 6352884
Drug: Insulin injection
RxNorm normalized name: diluent for insulin lispro and regular insulin INJECTION VIAL (ML)
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Insulin injection 30 to 60 minutes before breakfast
Trial: 6352884
Drug: Insulin injection
RxNorm normalized name: diluent for insulin lispro and regular insulin INJECTION VIAL (ML)
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Insulin injection 5 minutes prior to breakfast
Trial: 27271658
Drug: High-concentration glucose
RxNorm normalized name: methyl salicylate
DrugBank: Methyl salicylate (DB09543)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: High-concentration glucose solution (250 mL containing 50% glucose)
Trial: 27271658
Drug: Oral supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral supplementation plus high-concentration glucose solution
Trial: 27271658
Drug: 8.5% amino
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8.5% amino acids solution
Trial: 27271658
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (oral supplementation only)
Trial: 16163098
Drug: Infiltration solutions
RxNorm normalized name: Autologous tumor infiltrating lymphocytes
DrugBank: Lifileucel (DB17107)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Infiltration solutions at body temperature (37 degrees C)
Trial: 16163098
Drug: Infiltration solutions
RxNorm normalized name: Autologous tumor infiltrating lymphocytes
DrugBank: Lifileucel (DB17107)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Infiltration solutions at room temperature (24 degrees C)
Trial: 10472853
Drug: E2 1
RxNorm normalized name: PGE2 10 MG Vaginal Insert
FDA approved: no
EMA approved: no
PMDA approved: no
Description: E2 1 mg with norethindrone acetate 0.1 mg
Trial: 10472853
Drug: E2 1
RxNorm normalized name: PGE2 10 MG Vaginal Insert
FDA approved: no
EMA approved: no
PMDA approved: no
Description: E2 1 mg with norethindrone acetate 0.25 mg
Trial: 10472853
Drug: E2 1
RxNorm normalized name: PGE2 10 MG Vaginal Insert
FDA approved: no
EMA approved: no
PMDA approved: no
Description: E2 1 mg with norethindrone acetate 0.5 mg
Trial: 10472853
Drug: E2 1
RxNorm normalized name: PGE2 10 MG Vaginal Insert
FDA approved: no
EMA approved: no
PMDA approved: no
Description: E2 1 mg (unopposed)
Trial: 9087885
Drug: Treatment suggested
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment suggested by the trained ART (N = 21)
Trial: 9087885
Drug: Treatment suggested
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment suggested by ART
Trial: 1846790
Drug: Dichloroacetate (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dichloroacetate (50 mg/kg body weight)
Trial: 29921734
Drug: Intravenous epoetin
RxNorm normalized name: Epoetin
DrugBank: Erythropoietin (DB00016)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous epoetin alfa-epbx
Trial: 29921734
Drug: Intravenous epoetin
RxNorm normalized name: Epoetin
DrugBank: Erythropoietin (DB00016)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous epoetin alfa
Trial: 24925713
Drug: Docosahexaenoic acid-enriched
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Docosahexaenoic acid-enriched fish oil (600 mg daily)
Trial: 22250633
Drug: Auricular acupuncture
RxNorm normalized name: fluocinolone
DrugBank: Fluocinolone (DB12553)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Auricular acupuncture (weekly for 10 weeks)
Trial: 22250633
Drug: 0.1% tretinoin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.1% tretinoin ointment (topically for 10 weeks)
Trial: 11794427
Drug: Step-down therapy
RxNorm normalized name: Kool-Down
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Step-down therapy with pravastatin (dosing frequency changed from daily to every other day)
Trial: 11794427
Drug: Step-down therapy
RxNorm normalized name: Kool-Down
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Step-down therapy with pravastatin (daily dose halved)
Trial: 10463515
Drug: Sparfloxacin 200/100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sparfloxacin 200/100 mg
Trial: 10463515
Drug: Sparfloxacin 400/200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sparfloxacin 400/200 mg
Trial: 10463515
Drug: Sparfloxacin 800/400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sparfloxacin 800/400 mg
Trial: 7615103
Drug: Dopamine (DA)
DrugBank: Dopamine (DB00988)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dopamine (DA) infusion (0.4 micrograms/kg per minute)
Trial: 1696309
Drug: Chemotherapy (CT)
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy (CT) - two cycles of cisplatin, vindesine, and bleomycin
Trial: 1696309
Drug: Radiation therapy
RxNorm normalized name: Sensitizers used in photodynamic/radiation therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Radiation therapy (RT) - 55 Gy
Trial: 18524792
Drug: Adalimumab treatment
RxNorm normalized name: Adalimumab
DrugBank: Adalimumab (DB00051)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Adalimumab treatment for 24 weeks
Trial: 16326406
Drug: Transcatheter arterial
RxNorm normalized name: Echinacea, aerial parts
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transcatheter arterial chemoembolization (TACE) with Adriamycin (20 mg/m2), vincristine (1.5 mg/m2), and cisplatin (40 mg/m2) dispersed in 5-10 mL lipiodol, performed 1-3 times.